NOV 2021 - The hypothalamus and hindbrain have previously been implicated in appetite regulation, but drugs targeting these areas have not been as successful as hoped. Dr. J. Nicholas Betley, of the University of Pennsylvania, and Dr. Albert Chen, of…
SEPT 2021 - DCCR (Diazoxide Choline Controlled Release) is a once-daily treatment for hyperphagia and body composition being developed by Soleno Therapeutics for the PWS community. DCCR is thought to affect leptin pathways by opening KATP channels, and also to…
JUNE 2021 - The International PWS Clinical Trials Consortium have produced consensus definitions and descriptions of the key behavioural features of PWS, with the aim of providing standardised measures for treatment studies. FPWR have produced the infographic to the right…
AUG 2020 - Oxytocin (OT) is a naturally occurring hormone released from the hypothalamus in the brain. It is associated with maternal care, bonding, feeding in infancy, social cognition, OCD, anxiety and appetite control. Carbetocin is an oxytocin-like drug which is…
JUNE 2018 - Results of the phase 2 carbetocin trial (oxytocin-like nasal spray) have been published and phase 3 is expected to begin later this year. Carbetocin is similar to oxytocin, but specifically targets only the oxytocin receptor which may…
FEB 2018 - Diazoxide Choline Controlled Release (DCCR) is currently being developed by Soleno Therapeutics following a successful phase 2 trial in PWS patients which observed improvements in hyperphagia, a reduction of body fat and increase in lean body mass. They…